MedTrace Logo

Treatment of Advanced Hodgkin's Disease (Stages IIB-III-IV)

NCT00443677 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 307

Last updated 2009-03-20

No results posted yet for this study

Summary

The purpose of this study is to compare the toxicities of the COPPEBVCAD vs BEACOPP vs ABVD regimens.

Conditions

  • Advanced Hodgkin Disease

Interventions

DRUG

COPPEBVCAD vs BEACOPP vs ABVD

Sponsors & Collaborators

  • Gruppo Italiano Studio Linfomi

    lead OTHER

Principal Investigators

  • Paolo Gobbi, MD · GISL

  • Emilio Iannitto, MD · GISL

  • Giuseppe Polimeno, MD · GISL

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-04-30
Completion
2007-06-30

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00443677 on ClinicalTrials.gov